CinnoPar®


(Teriparatide)

More Dosing Accuracy, Touch the Patient Preference


Description

CinnoPar® is a recombinant formulation of endogenous parathyroid hormone (PTH), containing a 34-amino-acid sequence which is identical to the N-terminal portion of this hormone. Each Pen of CinnoPar® containing 600µg (250 µg /1ml) Teriparatide for subcutaneous injection, produced under EU GMP license.

Indication and Usage

CinnoPar® is indicated for treatment of glucocorticoid-induced osteoporosis, osteoporosis in men and osteoporosis in postmenopausal women who are at high risk for fractures.

Important safety information

  • CinnoPar® is contraindicated in patients who have hypersensitivity to teriparatide or any component of the formulation.
  • Orthostatic hypotension: Teriparatide may cause orthostatic hypotension. Transient orthostatic hypotension usually occurs within 4 hours of dosing and within the first several doses.
  • Osteosarcoma: [US Boxed Warning]: In animal studies, teriparatide has been associated with an increase in osteosarcoma; risk was dependent on both dose and duration. Avoid use in patients with an increased risk of osteosarcoma (including Paget disease, prior radiation, unexplained elevation of alkaline phosphatase, prior external beam or implant radiation therapy involving the skeleton, or in patients with open epiphyses). Do not use in patients with bone metastases, a history of skeletal metastases, hyperparathyroidism, or preexisting hypercalcemia. Not for use in patients with metabolic bone disease other than osteoporosis.
  • Urolithiasis: Use with caution in patients with active or recent urolithiasis because of risk of exacerbation.

FAQs

A

If your CinnoPar® Delivery Device isn't working as it should, please review the leaflet of product.

A

Active ingredient: Teriparatide.

Inactive ingredients: glacial acetic acid, sodium acetate (anhydrous), mannitol, metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.

 

A
  • CinnoPar® must be injected. You should inject it once a day in your thighs or abdomen subcutaneously. Before first injection, have your health care provider (physician, nurse or…) teach you the instruction.

You should not take CinnoPar® for more than 2 years over your lifetime.

• The daily dosing of the drug is 20 mcg which is equal to 0.08 cc.

•0.08 cc means 8 units on the Pen. For this purpose, rotate the dose dialer until “8” aligns with the pointer in the dose window to set dose to 8 units.

•Do not transfer the medicine from the CinnoPar® delivery device to a syringe. This can result in taking the wrong dose of CinnoPar®.

•CinnoPar® should look clear and colorless. Do not use CinnoPar® if it has particles in it, or if it is cloudy or colored.

•After each use, safely remove the needle, recap the delivery device, and put it back in the refrigerator right away.

•You can take CinnoPar® with or without food or drink.

A
  • Keep your CinnoPar® Delivery Device in the refrigerator between 36°F to 46°F (2°C to 8°C). Do not freeze the CinnoPar® Delivery Device. Do not use CinnoPar® if it has been frozen. Don’t use the medicine after expiration date.
  • Discard CinnoPar®, 30 days after first use even if it has medicine in it.
more